<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32737286</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Retromer stabilization results in neuroprotection in a model of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>3848</StartPage><MedlinePgn>3848</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3848</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-17524-7</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a fatal disease characterized by the degeneration of upper and lower motor neurons (MNs). We find a significant reduction of the retromer complex subunit VPS35 in iPSCs-derived MNs from ALS patients, in MNs from ALS post mortem explants and in MNs from SOD1G93A mice. Being the retromer involved in trafficking of hydrolases, a pathological hallmark in ALS, we design, synthesize and characterize an array of retromer stabilizers based on bis-guanylhydrazones connected by a 1,3-phenyl ring linker. We select compound 2a as a potent and bioavailable interactor of VPS35-VPS29. Indeed, while increasing retromer stability in ALS mice, compound 2a attenuates locomotion impairment and increases MNs survival. Moreover, compound 2a increases VPS35 in iPSCs-derived MNs and shows brain bioavailability. Our results clearly suggest the retromer as a valuable druggable target in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muzio</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1068-865X</Identifier><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy. luca.muzio@hsr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sirtori</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gornati</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Milan, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eleuteri</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fossaghi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brancaccio</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzoni</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Science and Technology (ISTM), CNR, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottoboni</LastName><ForeName>Linda</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5412-7785</Identifier><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feo</LastName><ForeName>Luca De</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quattrini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrangelo</LastName><ForeName>Eloise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Biophysics (IBF), CNR, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6451-1198</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics (IBF), CNR, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalone</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Milan, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biophysics (IBF), CNR, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comi</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marinelli</LastName><ForeName>Luciana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milani</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6098-3991</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics (IBF), CNR, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seneci</LastName><ForeName>Pierfausto</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9709-7344</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Milan, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Gianvito</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1295-9131</Identifier><AffiliationInfo><Affiliation>INSPE-Institute of Experimental Neurology, San Raffaele Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419572">VPS29 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419573">VPS35 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32737286</ArticleId><ArticleId IdType="pmc">PMC7395176</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-17524-7</ArticleId><ArticleId IdType="pii">10.1038/s41467-020-17524-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 2011;7:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004;27:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc. Natl Acad. Sci. USA. 2014;111:3620&#x2013;3625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3948312</ArticleId><ArticleId IdType="pubmed">24550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443:780&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051204</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, et al. Endolysosomal deficits augment mitochondria pathology in spinal motor neurons of asymptomatic fALS mice. Neuron. 2015;87:355&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4511489</ArticleId><ArticleId IdType="pubmed">26182418</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;15:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, McCaffery JM, Emr SD. A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J. Cell Biol. 1998;142:665&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148169</ArticleId><ArticleId IdType="pubmed">9700157</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, et al. The sorting nexin 3 retromer pathway regulates the cell surface localization and activity of a Wnt-activated polycystin channel complex. J. Am. Soc. Nephrol. 2017;28:2973&#x2013;2984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5619965</ArticleId><ArticleId IdType="pubmed">28620080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bean BD, Davey M, Conibear E. Cargo selectivity of yeast sorting nexins. Traffic. 2017;18:110&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">27883263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallon M, et al. A unique PDZ domain and arrestin-like fold interaction reveals mechanistic details of endocytic recycling by SNX27-retromer. Proc. Natl Acad. Sci. USA. 2014;111:E3604&#x2013;E3613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4156734</ArticleId><ArticleId IdType="pubmed">25136126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Wu Y, Belenkaya TY, Lin X. SNX3 controls Wingless/Wnt secretion through regulating retromer-dependent recycling of Wntless. Cell Res. 2011;21:1677&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357989</ArticleId><ArticleId IdType="pubmed">22041890</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN, Marcusson EG, Cereghino JL, Emr SD. Endosome to Golgi retrieval of the vacuolar protein sorting receptor, Vps10p, requires the function of the VPS29, VPS30, and VPS35 gene products. J. Cell Biol. 1997;137:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139870</ArticleId><ArticleId IdType="pubmed">9105038</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J. Cell Biol. 2004;165:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172094</ArticleId><ArticleId IdType="pubmed">15078903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C, et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 2011;89:162&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135796</ArticleId><ArticleId IdType="pubmed">21763482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011;89:168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135812</ArticleId><ArticleId IdType="pubmed">21763483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavodszky E, et al. Mutation in VPS35 associated with Parkinson&#x2019;s disease impairs WASH complex association and inhibits autophagy. Nat. Commun. 2014;5:3828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024763</ArticleId><ArticleId IdType="pubmed">24819384</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang FL, et al. VPS35 in dopamine neurons is required for &#x113;ndosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for alpha-synuclein degradation and prevention of pathogenesis of Parkinson&#x2019;s disease. J. Neurosci. 2015;35:10613&#x2013;10628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510296</ArticleId><ArticleId IdType="pubmed">26203154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi VJ, et al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 2014;10:443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. J. Cell Biol. 2004;165:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172078</ArticleId><ArticleId IdType="pubmed">15078902</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. The retromer complex&#x2014;endosomal protein recycling and beyond. J. Cell Sci. 2012;125:4693&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517092</ArticleId><ArticleId IdType="pubmed">23148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, et al. The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol. Dis. 2012;47:126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr MC, et al. A novel mammalian retromer component, Vps26B. Traffic. 2005;6:991&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190980</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MNJ. Retromer and its role in regulating signaling at endosomes. Prog. Mol. Subcell. Biol. 2018;57:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">30097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Convertino M, Das J, Dokholyan NV. Pharmacological chaperones: design and development of new therapeutic strategies for the treatment of conformational diseases. ACS Chem. Biol. 2016;11:1471&#x2013;1489.</Citation><ArticleIdList><ArticleId IdType="pubmed">27097127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chourasiya SS, et al. Azine-hydrazone tautomerism of guanylhydrazones: evidence for the preference toward the azine tautomer. J. Org. Chem. 2016;81:7574&#x2013;7583.</Citation><ArticleIdList><ArticleId IdType="pubmed">27494613</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamant S, Agranat I, Goldblum A, Cohen S, Atlas D. Beta-adrenergic activity and conformation of the antihypertensive specific alpha 2-agonist drug, guanabenz. Biochem. Pharm. 1985;34:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">2857565</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins MB, et al. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin. Cancer Res. 2001;7:486&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">11297238</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1983;26:212&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">6352237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001;46:3&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer M, Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 1999;38:1784&#x2013;1788.</Citation><ArticleIdList><ArticleId IdType="pubmed">29711196</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalvit C, Fogliatto G, Stewart A, Veronesi M, Stockman B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR. 2001;21:349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11824754</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams ET, et al. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting. Hum. Mol. Genet. 2018;27:3189&#x2013;3205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121197</ArticleId><ArticleId IdType="pubmed">29893854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourelatos Z, et al. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed by organelle-specific antibodies. Proc. Natl Acad. Sci. USA. 1990;87:4393&#x2013;4395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54116</ArticleId><ArticleId IdType="pubmed">2349244</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Matsuo A, Tooyama I, Julien JP. The endoplasmic reticulum-Golgi pathway is a target for translocation and aggregation of mutant superoxide dismutase linked to ALS. FASEB J. 2008;22:2476&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pubmed">18337461</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita Y, et al. Fragmentation of the Golgi apparatus of Betz cells in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 1999;163:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">10223416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan CP, et al. Retromer disruption promotes amyloidogenic APP processing. Neurobiol. Dis. 2011;43:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114192</ArticleId><ArticleId IdType="pubmed">21515373</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, et al. Defining peripheral nervous system dysfunction in the SOD-1G93A transgenic rat model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2014;73:658&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">24918640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluver H, Barrera E. A method for the combined staining of cells and fibers in the nervous system. J. Neuropathol. Exp. Neurol. 1953;12:400&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">13097193</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, et al. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 2006;9:108&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia. 2010;58:231&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784168</ArticleId><ArticleId IdType="pubmed">19672969</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. G., Chiu, J. &amp; Pratico, D. Full recovery of the Alzheimer&#x2019;s disease phenotype by gain of function of vacuolar protein sorting 35. Mol. Psychiatry10.1038/s41380-019-0364-x (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685773</ArticleId><ArticleId IdType="pubmed">30733594</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JG, Chiu J, Ramanjulu M, Blass BE, Pratico D. A pharmacological chaperone improves memory by reducing Abeta and tau neuropathology in a mouse model with plaques and tangles. Mol. Neurodegener. 2020;15:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6975032</ArticleId><ArticleId IdType="pubmed">31964406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, et al. Vps10 family proteins and the retromer complex in aging-related neurodegeneration and diabetes. J. Neurosci. 2012;32:14080&#x2013;14086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576841</ArticleId><ArticleId IdType="pubmed">23055476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MS, et al. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001;20:2180&#x2013;2190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125444</ArticleId><ArticleId IdType="pubmed">11331584</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent-Matha V, Derocq D, Prebois C, Katunuma N, Liaudet-Coopman E. Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J. Biochem. 2006;139:363&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376303</ArticleId><ArticleId IdType="pubmed">16567401</ArticleId></ArticleIdList></Reference><Reference><Citation>Miura E, et al. VPS35 dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson&#x2019;s disease. Neurobiol. Dis. 2014;71:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25107340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootz H, Weber E, Korhonen L, Lindholm D. Altered distribution and levels of cathepsinD and cystatins in amyotrophic lateral sclerosis transgenic mice: possible roles in motor neuron survival. Neuroscience. 2006;143:419&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973300</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis. 2001;8:933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. Proteasomes remain intact, but show early focal alteration in their composition in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2008;105:2353&#x2013;2366.</Citation><ArticleIdList><ArticleId IdType="pubmed">18315558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964&#x2013;1979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4737506</ArticleId><ArticleId IdType="pubmed">19741722</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat. Neurosci. 2009;12:627&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura N, et al. Characterization of a cis-Golgi matrix protein, GM130. J. Cell Biol. 1995;131:1715&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120691</ArticleId><ArticleId IdType="pubmed">8557739</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourelatos Z, Gonatas NK, Stieber A, Gurney ME, Dal Canto MC. The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc. Natl Acad. Sci. USA. 1996;93:5472&#x2013;5477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39270</ArticleId><ArticleId IdType="pubmed">8643599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng XT, et al. Characterization of LAMP1-labeled nondegradative lysosomal and endocytic compartments in neurons. J. Cell Biol. 2018;217:3127&#x2013;3139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6123004</ArticleId><ArticleId IdType="pubmed">29695488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahms NM, Olson LJ, Kim JJ. Strategies for carbohydrate recognition by the mannose 6-phosphate receptors. Glycobiology. 2008;18:664&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733771</ArticleId><ArticleId IdType="pubmed">18621992</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvvuri M, Feng W, Mathis A, Krise JP. A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm. Res. 2004;21:26&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14984254</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA. 2000;97:12571&#x2013;12576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18805</ArticleId><ArticleId IdType="pubmed">11050163</ArticleId></ArticleIdList></Reference><Reference><Citation>Schagger H, von Jagow G. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal. Biochem. 1991;199:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1812789</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen PJ, Korswagen HC. Sorting nexins provide diversity for retromer-dependent trafficking events. Nat. Cell Biol. 2011;14:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613977</ArticleId><ArticleId IdType="pubmed">22193161</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, et al. Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann. Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YK, Shin KS, Yuan J, Kang SJ. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells. J. Neurochem. 2008;104:993&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">18233996</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Retzlaff M, Roos T, Frydman J. Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 2011;3:a004374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140689</ArticleId><ArticleId IdType="pubmed">21746797</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Kurisu J, Tsukita K, Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 2002;83:1030&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">12437574</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 2016;35:1656&#x2013;1676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrionero A, Horvitz HR. A C9orf72 ALS/FTD ortholog acts in endolysosomal degradation and lysosomal homeostasis. Curr. Biol. 2018;28:1522&#x2013;1535 e1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">29731301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonatas NK, et al. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am. J. Pathol. 1992;140:731&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886164</ArticleId><ArticleId IdType="pubmed">1546747</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004;75:822&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuling E, et al. Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. J. Neurosci. 2007;27:9801&#x2013;9815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672975</ArticleId><ArticleId IdType="pubmed">17804640</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong R, et al. Endosome-ER contacts control actin nucleation and retromer function through VAP-dependent regulation of PI4P. Cell. 2016;166:408&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963242</ArticleId><ArticleId IdType="pubmed">27419871</ArticleId></ArticleIdList></Reference><Reference><Citation>Stieber A, Gonatas JO, Gonatas NK. Aggregates of mutant protein appear progressively in dendrites, in periaxonal processes of oligodendrocytes, and in neuronal and astrocytic perikarya of mice expressing the SOD1(G93A) mutation of familial amyotrophic lateral sclerosis. J. Neurol. Sci. 2000;177:114&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">10980307</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GM, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierro A, et al. Functional architecture of the retromer cargo-recognition complex. Nature. 2007;449:1063&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377034</ArticleId><ArticleId IdType="pubmed">17891154</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi C, et al. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis. 2018;9:250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833860</ArticleId><ArticleId IdType="pubmed">29445154</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens JC, et al. Modification of superoxide dismutase 1 (SOD1) properties by a GFP tag&#x2013;implications for research into amyotrophic lateral sclerosis (ALS) PLoS ONE. 2010;5:e9541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833207</ArticleId><ArticleId IdType="pubmed">20221404</ArticleId></ArticleIdList></Reference><Reference><Citation>Du ZW, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat. Commun. 2015;6:6626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4375778</ArticleId><ArticleId IdType="pubmed">25806427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>